Skip to main content
Have a personal or library account? Click to login
Significance of nuclear factor - kappa beta activation on prostate needle biopsy samples in the evaluation of Gleason score 6 prostatic carcinoma indolence Cover

Significance of nuclear factor - kappa beta activation on prostate needle biopsy samples in the evaluation of Gleason score 6 prostatic carcinoma indolence

Radiology and Oncology
Volume 54 (2020): Issue 2 (June 2020)
By: ,  ,  ,  ,  ,   and    
Open Access
|Apr 2020
Figures & tables

Figures & Tables

Table 1

Patient characteristics

General, N = 123
Mean Age, year, (range)63.6 (50–75)
Mean init. PSA, ng/ml, (range)5.32 (1,32–9,51)
Mean Prostate V, ml, (range)38.3 (14–97)
Mean Biopsy cores, n, (range)9.6 (8–10)
Total Biopsy cores, n1.180
Clinical stage
          T1, n, (%)113 (91.9)
          T2, n, (%)10 (8.1)
Biopsy GS 3+3=6, n, (%)123 (100)
Surgery
          ELRP, n, (%)87 (70.7)
          N-S ELRP, n, (%)36 (29.3)
Pathological result after RP
N = 123N of total P% of total P
pT classification
     T29678.0
     T3a2318.7
     T3b43.3
Surgical margins
     Positive1310.6
     Negative11089.4
Gleason score
     3+3=67964.2
     3+4=73730.1
     4+3=775.7
Biochemical progression after RP
N = 118N (%)GS 6GS 7
BPN( %)N( %)
PSA 0,05–0.19 ng/ml14 (11.8)8(57.1)6(42.9)
PSA ≥ 0,2 ng/ml6 (5.1)3(50)3(50)

[i] BP = biochemical progression; ELRP = laparoscopic radical prostatectomy; GS = Gleason score; N-S ELRP = “nerve-sparing” extraperitoneal laparoscopic radical prostatectomy; PSA = Prostate-specific antigen; RP = radical prostatectomy; V = volume

Table 2

Association of nuclear factor-kappa beta (NF-κB) p65 expression status in cytoplasm with pathological findings

N = 123NNF-κB p65 expressionP
negativepositive
pT status
pT2964848
pT32712150.667*
Surg. m.
          Negative110537
          Positive13760.774**
GS
3 + 3 = 6793940
3 + 4 = 7371720
4 + 3 = 77520.465***

[i] * pT2 versus pT3, **negative versus positive surgical margin, ***3 + 3 = 6 versus 3 + 4 = 7 versus 4 + 3 = 7

GS = Gleason score; Surg. M. = surgical margin

Figure 1

Recurrence-free survival (RFS) in patients with positive and negative nuclear factor-kappa beta (NF-κB) p65 expression status in cytoplasm (N = 118).

Table 3

Cytoplasmic nuclera factor-kappa beta (NF-κB) p65 expression status in biopsy group postoperative Gleason score (GS) 6 and control biopsy group postoperative GS 7

NNF-κB p65 expressionP
negativepositive
3 + 3 = 61236063
3 + 4 = 730327<0.001*
4 + 3 = 730030<0.001**

[i] * 3 + 3 = 6 versus 3 + 4 = 7, **3 + 3 = 6 versus 4 + 3 = 7

Table 4

Multivariate analysis of cytoplasmic nuclear factor-kappa beta (NF-κB) p65 expression and other clinicopathologic variables associated with recurrence-free survival (RFS)

Hazard ratio (95% CI)P
Cytoplasmic NF-κB p65 expression (negative vs. positive)2.367 (0.908–6.170)0.078
Postoperative Gleason score (6 vs. 7)1.105 (0.406–3.008)0.845
Surgical (negative margin vs. positive)4.845 (1.646–14.260)0.004
Pathologic (T2 vs. T3) stage1.041 (0.339–3.194)0.944
Figure 2

Recurrence-free survival (RFS) in patients with positive and negative nuclear factor-kappa beta (NF-κB) p65 expression status in nucleus (N = 118).

Table 5

Association of nuclear factor-kappa beta (NF-κB) p65 expression status in nucleus with pathological findings

N = 123NNF-κB p65 expressionP
negativepositive
pT status
          pT2968115
          pT3272250.769*
Surg. m.
          Negative1109218
          Positive131121**
GS
3 + 3 = 6796613
3 + 4 = 737316
4 + 3 = 77610.989***

[i] * pT2 versus pT3, **negative versus positive surgical margin, *** 3 + 3 = 6 versus 3 + 4 = 7 versus 4 + 3 = 7

GS = Gleason score; Surg. M. = surgical margin

Table 6

Nuclear factor-kappa beta (NF-κB) p65 expression status in biopsy group GS 6 and control biopsy group GS 7

NNF-κB p65 expressionP
negativepositive
3+3=612310320
3+4=7302460.596*
4+3=73017130.003**

[i] * 3+3=6 versus 3+4=7, **3+3=6 versus 4+3=7

Figure 3

Immunohistochemistry of nuclear factor-kappa beta (NF-κB) p65. (A) Positive cytoplasmic staining (GS 6). (B) Positive nuclear staining. (C) Positive cytoplasmic staining (GS 7). (D) Positive nuclear staining.

Table 7

Multivariate analysis of nuclear factor-kappa beta (NF-κB) p65 expression and other clinicopathologic variables associated with recurrence-free survival (RFS; recurrence defined as PSA ≥ 0.05)

Hazard ratio (95% CI)P
NF-(negative κB p65 expression vs. positive)0.254 (0.034–1.915)0.184
Postoperative score (6 vs. 7) Gleason1.078 (0.400–2.907)0.882
Surgical (negative margin vs. positive)4.838 (1.674–13.983)0.004
Pathologic (T2 vs. T3) stage1.232 (0.409–3.705)0.711
DOI: https://doi.org/10.2478/raon-2020-0019 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 194 - 200
Submitted on: Jan 3, 2020
Accepted on: Mar 24, 2020
Published on: Apr 21, 2020
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
nuclear factor-kappa beta,
prostatic cancer,
Gleason 6,
needle biopsy sample
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2020 Marko Zupancic, Boris Pospihalj, Snezana Cerovic, Barbara Gazic, Primoz Drev, Marko Hocevar, Andraz Perhavec, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 54 (2020): Issue 2 (June 2020)
Previous article
Next article